Last reviewed · How we verify
TMC125 twice daily
At a glance
| Generic name | TMC125 twice daily |
|---|---|
| Sponsor | St Stephens Aids Trust |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Blood sodium decreased
- Blood bilirubin increased
- Blood bicarbonate decreased
- Blood glucose increased
- Blood phosphorus decreased
- Blood alkaline phosphatase increased
- Aspartate aminotransferase increased
- Blood cholesterol increased
- Neutrophil count decreased
- Low density lipoprotein increased
- Pyrexia
- Cough
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants (PHASE1)
- B-free Multistage Trial (PHASE4)
- Optimizing Treatment for Treatment-Experienced, HIV-Infected People (PHASE3)
- Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children (PHASE1, PHASE2)
- Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL (PHASE2)
- Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TMC125 twice daily CI brief — competitive landscape report
- TMC125 twice daily updates RSS · CI watch RSS
- St Stephens Aids Trust portfolio CI